Immunomedics (IMMU) Receives New U.S. Patent Covering IMMU-130
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 4/23/2024
- Stocks gear up for Big Tech earnings; yen toys with danger zone
- JPMorgan is worried about further S&P 500 sell-off potential
- Oil rises on robust EU data as Mideast tensions linger
- China acquired top-end Nvidia AI chips despite recent US ban- Reuters
- SAP Q1 results fall short of Wall Street estimates as transformation kicks off
- Fisker (FSR) Appoints Michael Healy as Chief Restructuring Officer
- Kroger (KR), Albertsons and C&S Wholesale Grocers Announce an Updated and Expanded Divestiture Plan
- Costar Group (CSGP) to Acquire Matterport (MTTR) for $5.50/sh Cash and Stock
- Jaguar Health (JAGX) Files $75M Mixed Shelf
- Apple (AAPL) PT Lowered to $210 at Morgan Stanley, 'We'd buy post-earnings weakness'
- After-hours movers: Cadence Design Systems, Cleveland-Cliffs, Riot Platforms, and more
- Midday movers: Tesla, Li Auto and CNH Industrial fall; Salesforce rises
- Midday movers: Netflix, Super Micro fall; Paramount Global gains
- After-hours movers: Netflix, Intuitive Surgical, Nordstrom, KB Home
- Midday movers: Tesla, Blackstone, Las Vegas Sands fall; DR Horton rises
Immunomedics Announces New Patents for Antibody-Drug Conjugates and Vaccines for Cancer Therapy
October 19, 2016 7:00 AM EDTMORRIS PLAINS, N.J., Oct. 19, 2016 (GLOBE NEWSWIRE) -- Immunomedics, Inc., (Nasdaq: IMMU) today announced the issuance of U.S. Patent 9,458,242 for additional claims under the patent family Dosages of immunoconjugates of antibodies and SN-38 for improved efficacy and decreased toxicity. This new patent, which will expire in July 2033, covers the use of labetuzumab govitecan (IMMU-130), the Companys second... More
